TrialHematological oncology2020

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Ajai Chari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.